Skylands Capital LLC Buys 13,650 Shares of Icon Plc $ICLR

Skylands Capital LLC increased its stake in Icon Plc (NASDAQ:ICLR) by 241.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,300 shares of the medical research company’s stock after buying an additional 13,650 shares during the period. Skylands Capital LLC’s holdings in Icon were worth $2,136,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Sanctuary Advisors LLC boosted its position in Icon by 1.1% in the 4th quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock valued at $899,000 after buying an additional 56 shares during the period. Geneos Wealth Management Inc. increased its position in shares of Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after acquiring an additional 56 shares during the period. New Wave Wealth Advisors LLC raised its stake in shares of Icon by 5.1% during the fourth quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock valued at $270,000 after acquiring an additional 72 shares in the last quarter. Signaturefd LLC boosted its holdings in shares of Icon by 12.6% in the fourth quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock valued at $117,000 after purchasing an additional 72 shares during the period. Finally, Janney Montgomery Scott LLC boosted its holdings in shares of Icon by 0.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 23,942 shares of the medical research company’s stock valued at $4,363,000 after purchasing an additional 93 shares during the period. Institutional investors own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on ICLR shares. Truist Financial raised their price objective on Icon from $139.00 to $159.00 and gave the stock a “hold” rating in a report on Friday, May 29th. TD Cowen upped their target price on Icon from $164.00 to $197.00 and gave the stock a “buy” rating in a report on Thursday. Citigroup increased their price target on Icon from $140.00 to $165.00 and gave the stock a “neutral” rating in a research report on Thursday. Barclays raised their price target on Icon from $160.00 to $175.00 and gave the company an “equal weight” rating in a research note on Thursday. Finally, Royal Bank Of Canada upgraded Icon from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $126.00 to $185.00 in a report on Thursday. Eight research analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $170.19.

Icon Stock Performance

Shares of ICLR stock opened at $169.86 on Friday. The firm has a market cap of $13.01 billion, a price-to-earnings ratio of 30.22, a PEG ratio of 8.47 and a beta of 1.26. Icon Plc has a 52-week low of $66.57 and a 52-week high of $211.00. The company has a quick ratio of 1.10, a current ratio of 1.14 and a debt-to-equity ratio of 0.31. The company’s 50 day moving average is $129.64 and its 200 day moving average is $138.28.

Icon (NASDAQ:ICLR) last posted its earnings results on Tuesday, June 23rd. The medical research company reported $2.50 earnings per share for the quarter, topping analysts’ consensus estimates of $2.43 by $0.07. The company had revenue of $2.03 billion during the quarter, compared to analyst estimates of $1.98 billion. Icon had a return on equity of 8.73% and a net margin of 5.35%.Icon’s revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.43 earnings per share. On average, sell-side analysts anticipate that Icon Plc will post 9.39 EPS for the current fiscal year.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.